2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)
Bioanalysis · 2023
DOI: 10.4155/bio-2023-0135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioanalysis, 2023. Verfasst von Luying Pan und 59 weiteren Autor:innen. Beteiligte Einrichtung: Takeda, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Prescription Drugs. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 86 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda, Cambridge, MA, USA.
- Bristol Myers Squibb, Lawrenceville, NJ, USA.
- GlaxoSmithKline, Rixensart, Belgium.
- US FDA, Silver Spring, MD, USA.
- UK MHRA, London, UK.
- Vertex, Boston, MA, USA.
Zitieren
APA
Pan, L., Mora, J., Walravens, K., Wagner, L., Hopper, S., Loo, L., Bettoun, D., Bond, S., Dessy, F., Downing, S., Garofolo, F., Gupta, S., Henderson, N., Irwin, C., Ishii-Watabe, A., Kar, S., Jawa, V., Joseph, J., Malvaux, L., …, & Rajadhyaksha, M. (2023). 2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach). Bioanalysis. https://doi.org/10.4155/bio-2023-0135
Vancouver
Pan L, Mora J, Walravens K, Wagner L, Hopper S, Loo L, et al. 2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach). Bioanalysis. 2023. doi:10.4155/bio-2023-0135
BibTeX
@article{Pan2023,
author = {Pan, Luying and Mora, Johanna and Walravens, Karl and Wagner, Leslie and Hopper, Shirley and Loo, Lina and Bettoun, David and Bond, Sarah and Dessy, Francis and Downing, Sean and Garofolo, Fabio and Gupta, Soumi and Henderson, Neil and Irwin, Chad and Ishii-Watabe, Akiko and Kar, Sumit and Jawa, Vibha and Joseph, Julie and Malvaux, Ludovic and Marshall, Jean-Claude and McDevitt, Jessica and Mohapatra, Susovan and Seitzer, Jessica and Smith, Justin and Solstad, Therese and Sugimoto, Hiroshi and Tounekti, Omar and Wu, Bonnie and Wu, Yuling and Xu, Yuanxin and Xu, Joshua and Yamamoto, Takenori and Yang, Lin and Torri, Albert and Kirshner, Susan and Maxfield, Kimberly and Vasconcelos, Joao Pedras and Abhari, Mohsen Rajabi and Verthelyi, Daniela and Brodsky, Eric and Carrasco-Triguero, Montserrat and Kamerud, John and Andisik, Matthew and Baltrukonis, Daniel and Bivi, Nicoletta and Cludts, Isabelle and Coble, Kelly and Gorovits, Boris and Gunn, George R and Gupta, Swati and Millner, Anders Holm and Joyce, Alison and Kubiak, Robert J and Kumar, Seema and Liao, Karen and Manangeeswaran, Mohanraj and Partridge, Michael and Pine, Samuel and Poetzl, Johann and Rajadhyaksha, Manoj},
title = {2022 White Paper on Recent Issues in Bioanalysis: Fda Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, Lnp & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, Ada Affinity, Risk-Based Approaches, Ngs, Qpcr, Ddpcr Assays ( Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach)},
journal = {Bioanalysis},
year = {2023},
doi = {10.4155/bio-2023-0135}
}
EUVIMED